GSK plc (LON/NYSE:GSK) has announced that, further to its announcement on 5 October 2023, GSK has agreed to sell 270m ordinary shares in Haleon plc at a price of 328 pence per share, raising gross proceeds of approximately £885.6m.
Following settlement of the Placing, GSK will hold 685m1 ordinary shares in Haleon, representing approximately 7.4% of the issued share capital of Haleon.
GSK and Pfizer Inc. (which holds a 32% stake in Haleon), have each undertaken not to dispose of any further shares in Haleon for a period of 60 days following settlement of the Placing, subject to certain customary exceptions and waiver by BofA Securities and Citigroup Global Markets Limited.
(1) Excluding shares in Haleon held by the GSK employee share ownership trust.
